WHAT IS CLAIMED IS

1. The use of a vascular-hyperpermeability-inhibiting amount of danazol or a pharmaceutically acceptable salt thereof and a second drug, for the manufacture of a medicament for the treatment of a disease or condition mediated by vascular hyperpermeability in an animal, wherein the vascular-hyperpermeability-inhibiting amount is from 1 ng to 100 mg and wherein the second drug is an angiotensin converting enzyme (ACE) inhibitor or an ACE receptor antagonist, and wherein the disease or condition is selected from the group consisting of diabetes, atherosclerosis, hypertension, a vascular complication of diabetes, an acute lung injury, acute respiratory distress syndrome, age-related macular degeneration, cerebral edema, choroidal edema, choroiditis, coronary microvascular disease, cerebral microvascular disease, Eals disease, edema caused by injury, edema associated with hypertension, glomerular vascular leakage, hemorrhagic shock, Irvine Gass Syndrome, ischemia, macular edema, nephritis, nephropathies, nephrotic edema, nephrotic syndrome, neuropathy, organ failure due to edema, pre-eclampsia, pulmonary edema, pulmonary hypertension, renal failure, retinal edema, retinal hemorrhage, retinal vein occlusion, retinitis, retinopathy, silent cerebral infarction, systemic inflammatory response syndrome, transplant glomerulopathy, uveitis, vascular leakage syndrome, vitreous hemorrhage or Von Hipple Lindau disease.

2. The use as claimed in claim 1 wherein the disease or condition is diabetes.

3. The use as claimed in claim 1 wherein the disease or condition is atherosclerosis.

4. The use as claimed in claim 1 wherein the disease or condition is hypertension.

5. The use as claimed in claim 1 wherein the disease or condition is a macular edema.

6. The use as claimed in claim 1 wherein the disease or condition is a neuropathy.

7. The use as claimed in claim 1 wherein the disease or condition is a retinopathy.

8. The use as claimed in claim 1 wherein the vascular complication is edema, accumulation of low density lipoproteins in subendothelial space, accelerated atherosclerosis, accelerated aging of vessel walls in the brain, myocardial edema, myocardial fibrosis, diastolic dysfunction, diabetic cardiomyopathy, retardation of lung development in the fetuses of diabetic mothers, alterations of one or more pulmonary physiological parameters, increased susceptibility to infections, vascular hyperplasy in the mesentery, diabetic neuropathy, diabetic macular edema, diabetic retinopathy, diabetic nephropathy, or redness, discoloration, dryness and ulcerations of the skin.

9. The use as claimed in claim 8wherein the vascular complication is edema.

10. The use as claimed in claim 8 wherein the vascular complication is diabetic cardiomyopathy.

11. The use as claimed in claim 8 wherein the vascular complication is diabetic neuropathy.

12. The use as claimed in claim 8 wherein the vascular complication is diabetic macular edema.

13. The use as claimed in claim 8 wherein the vascular complication is diabetic retinopathy.

14. The use as claimed in claim 13 wherein the diabetic retinopathy is nonproliferative diabetic retinopathy.

15. The use as claimed in claim 8 wherein the vascular complication is diabetic nephropathy.

16. The use as claimed in any one of claims 1-15 wherein the danazol is in an oral formulation.

17. The use as claimed in any one of claims 1-16 wherein the animal is a human.

18. The use as claimed in claim 1 wherein vascular-hyperpermeability-inhibiting amount of danazol is from 1 mg to 100 mg.

19. The use as claimed in claim 18 wherein vascular-hyperpermeability-inhibiting amount of danazol is from 10 mg to 90 mg.

20. The use as claimed in claim 1 wherein the second drug is a drug effective to inhibit vascular hyperpermeability.

21. A pharmaceutical composition comprising a pharmaceutically-acceptable carrier, danazol or a pharmaceutically acceptable salt thereof in an amount between 1 ng and 100 mg and a second drug, wherein the second drug is an angiotensin converting enzyme (ACE) inhibitor or an ACE receptor antagonist.

22. The composition of claim 21 wherein the second drug is one that inhibits vascular hyperpermeability.

23. A kit comprising a vascular-hyperpermeability-inhibiting amount of danazol or a pharmaceutically acceptable salt thereof and a second drug wherein the second drug is an angiotensin converting enzyme (ACE) inhibitor or an ACE receptor antagonist.